Within the drug repositioning Market, therapeutic applications span a wide spectrum of medical disciplines, with oncology, neurology, and infectious diseases commanding significant focus. Oncology remains a leading application area due to the heterogeneous nature of cancer and the frequent emergence of drug resistance. Repurposing existing immunotherapies, enzyme inhibitors, or targeted therapies offers cancer patients new combination treatment options without adding excessive toxicity burdens.

Neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS), represent another major focus for drug repurposing. Given the high failure rates of novel Central Nervous System (CNS) therapies in clinical trials, repurposing drugs with established blood-brain barrier permeability provides a viable alternative pathway for slowing disease progression and improving patient outcomes.

To examine detailed application breakdowns and target disease market projections, access the dedicated drug repositioning Market study.

Infectious disease management has also demonstrated the utility of drug repositioning during global public health emergencies. Rapidly evaluating established antiviral, antibacterial, and anti-inflammatory molecules allows health systems to respond swiftly to emerging viral strains and pandemic threats, illustrating the critical public safety value of flexible drug discovery models.